Sign inJoin waitlistJoin the waitlist

Benjamin Heyman

Hematologist · University of California (San Diego) Medical Center

Credentials: · · · · ·

History

University of California (San Diego) Medical Center · City of Hope National Medical Center
Present

Hematology and Medical Oncology
Duke University Hospital
2014–2017
Internal Medicine
Duke University Hospital
2011–2014
University of Virginia School of Medicine
2007–2011

Research

Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment
Journal of Clinical Investigation · 2019 · 241 citations
Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing
Open Forum Infectious Diseases · 2016 · 63 citations
Mechanisms of heparanase inhibitors in cancer therapy
Review · Experimental Hematology · 2016 · First of 2 authors · 47 citations

MC
Michael Choi
7 papers
Thomas Kipps
5 papers
YY
Yiping Yang
5 papers
Anne Beaven
3 papers
Nisha Hariharan
3 papers · 3 as a fellow
AP
Amy Petty
2 papers
Catriona Jamieson
2 papers
Dan Kaufman
2 papers
HW
Huan-You Wang
2 papers
Aaron Miller
1 paper
Adam Barnett
1 paper · 1 as a resident
AC
Aileen Cohen
1 paper

Clinical trials

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Principal investigator · Not yet recruiting · Phase 2
City of Hope Medical Center
2026–2029
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Principal investigator · Active not recruiting · Phase 2
University of California, San Diego
2020–2026
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2030
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2028